Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jacobio Pharmaceuticals has announced that the U.S. FDA has approved their Investigational New Drug application for JAB-23E73, a drug aimed at treating cancer patients with KRAS mutations. The company plans to proceed with phase I/IIa clinical trials in the U.S. and awaits approval for trials in China. This announcement highlights Jacobio’s ongoing commitment to innovative cancer treatment solutions.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.